{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:15:12Z","timestamp":1783653312409,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04312-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:44:06Z","timestamp":1779165846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Classification and regression trees to identify COPD subgroups in clinical trial populations: insights from the IMPACT trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Lucile","family":"Regard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Paillasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"2","key":"4312_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410\u20139. https:\/\/doi.org\/10.1183\/13993003.01359-2015.","journal-title":"Eur Respir J"},{"issue":"5","key":"4312_CR2","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.009","volume":"153","author":"O Le Rouzic","year":"2018","unstructured":"Le Rouzic O, Roche N, Cortot AB, et al. Defining the Frequent Exacerbator Phenotype in COPD: A Hypothesis-Free Approach. Chest. 2018;153(5):1106\u201315. https:\/\/doi.org\/10.1016\/j.chest.2017.10.009.","journal-title":"Chest"},{"issue":"4","key":"4312_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1378\/chest.08-2062","volume":"135","author":"PR Burgel","year":"2009","unstructured":"Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135(4):975\u201382.","journal-title":"Chest"},{"issue":"2","key":"4312_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.rmed.2014.12.006","volume":"109","author":"L McGarvey","year":"2015","unstructured":"McGarvey L, Lee AJ, Roberts J, Gruffydd-Jones K, McKnight E, Haughney J. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med. 2015;109(2):228\u201337. https:\/\/doi.org\/10.1016\/j.rmed.2014.12.006.","journal-title":"Respir Med"},{"key":"4312_CR5","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1164\/ajrccm.153.5.8630597","volume":"153","author":"J Vestbo","year":"1996","unstructured":"Vestbo J, Prescott E, Lange P, The Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med. 1996;153:1530\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"4312_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338. https:\/\/doi.org\/10.1056\/NEJMoa0909883.","journal-title":"N Engl J Med"},{"issue":"3","key":"4312_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1183\/09031936.00175109","volume":"36","author":"PR Burgel","year":"2010","unstructured":"Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3):531\u20139. https:\/\/doi.org\/10.1183\/09031936.00175109.","journal-title":"Eur Respir J"},{"issue":"5","key":"4312_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/thx.2010.154484","volume":"66","author":"J Garcia-Aymerich","year":"2011","unstructured":"Garcia-Aymerich J, G\u00f3mez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430\u20137. https:\/\/doi.org\/10.1136\/thx.2010.154484.","journal-title":"Thorax"},{"issue":"6","key":"4312_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jbi.2009.05.008","volume":"42","author":"M Paoletti","year":"2009","unstructured":"Paoletti M, Camiciottoli G, Meoni E, et al. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes. J Biomed Inf. 2009;42(6):1013\u201321. https:\/\/doi.org\/10.1016\/j.jbi.2009.05.008.","journal-title":"J Biomed Inf"},{"issue":"7","key":"4312_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1164\/rccm.201209-1665OC","volume":"187","author":"LEGW Vanfleteren","year":"2013","unstructured":"Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728\u201335. https:\/\/doi.org\/10.1164\/rccm.201209-1665OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"4312_CR11","doi-asserted-by":"publisher","first-page":"e51048","DOI":"10.1371\/journal.pone.0051048","volume":"7","author":"PR Burgel","year":"2012","unstructured":"Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS ONE. 2012;7(12):e51048. https:\/\/doi.org\/10.1371\/journal.pone.0051048.","journal-title":"PLoS ONE"},{"issue":"2","key":"4312_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1183\/09031936.00228511","volume":"40","author":"PR Burgel","year":"2012","unstructured":"Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J. 2012;40(2):495\u20136. https:\/\/doi.org\/10.1183\/09031936.00228511.","journal-title":"Eur Respir J"},{"key":"4312_CR13","doi-asserted-by":"publisher","unstructured":"Burgel PR, Paillasseur JL, Janssens W, et al. A simple algorithm for the identification of clinical COPD phenotypes. Eur Respir J. 2017;50(5). https:\/\/doi.org\/10.1183\/13993003.01034-2017.","DOI":"10.1183\/13993003.01034-2017"},{"key":"4312_CR14","doi-asserted-by":"publisher","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med Published online April. 2018;18. https:\/\/doi.org\/10.1056\/NEJMoa1713901.","DOI":"10.1056\/NEJMoa1713901"},{"issue":"12","key":"4312_CR15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","volume":"201","author":"DA Lipson","year":"2020","unstructured":"Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508\u201316. https:\/\/doi.org\/10.1164\/rccm.201911-2207OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4312_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1916046.","journal-title":"N Engl J Med"},{"key":"4312_CR17","doi-asserted-by":"publisher","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study. Am J Respir Crit Care Med Published online November. 2020;30. https:\/\/doi.org\/10.1164\/rccm.202006-2618OC.","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"4312_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/COPD.S196383","volume":"14","author":"D Singh","year":"2019","unstructured":"Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy delays COPD clinically important deterioration vs ICS\/LABA, LAMA, or LABA\/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;14:531\u201346. https:\/\/doi.org\/10.2147\/COPD.S196383.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"4312_CR19","doi-asserted-by":"publisher","unstructured":"Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med Published online July. 2019;4. https:\/\/doi.org\/10.1016\/S2213-2600(19)30190-0.","DOI":"10.1016\/S2213-2600(19)30190-0"},{"key":"4312_CR20","unstructured":"Pages J. Multiple Factor Analysis by Example Using R. Boca Raton, FL. Chapman & Hall\/CRC; 2014."},{"key":"4312_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1465-9921-15-64","volume":"15","author":"PR Burgel","year":"2014","unstructured":"Burgel PR, Paillasseur JL, Dusser D, et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res. 2014;15:64. https:\/\/doi.org\/10.1186\/1465-9921-15-64.","journal-title":"Respir Res"},{"key":"4312_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12890-019-0882-y","volume":"19","author":"L Pahus","year":"2019","unstructured":"Pahus L, Burgel P, Roche N, Paillasseur J, Chanez P. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019;19:127. https:\/\/doi.org\/10.1186\/s12890-019-0882-y.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"4312_CR23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021322","volume":"350","author":"BR Celli","year":"2004","unstructured":"Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"4312_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/15412555.2018.1484440","volume":"16","author":"P Almagro","year":"2019","unstructured":"Almagro P, Mart\u00ednez-Camblor P, Miravitlles M, et al. External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD. 2019;16(1):8\u201317. https:\/\/doi.org\/10.1080\/15412555.2018.1484440.","journal-title":"COPD"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04312-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:41:23Z","timestamp":1783651283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04312-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4312"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04312-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The IMPACT trial was performed in 37 countries from June 2014 through July 2017. It was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki and received approval from local institutional review boards or independent ethics committees. All the patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NR reports personal fees from GSK, AstraZeneca, Sanofi, Chiesi, Pfizer, Austral, Biosency, Zambon, MSD, and Menarini for consulting or speaking engagements, and institutional support from Chiesi, GSK, and Pfizer. He also serves as Chair of the ERS Science Council. PRB reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Insmed, MSD, Pfizer, Sanofi, Vertex, and Viatris, and institutional support from AstraZeneca and Chiesi. LR reports personal fees from AstraZeneca, Chiesi, GSK, and Sanofi, and institutional support for meeting attendance from AstraZeneca, Chiesi, and Sanofi. JLP is employed by Effi-Stat.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}